f Post-Approval Studies (PAS) Database
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database

  • Print
  • Share
  • E-mail

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


ProAct Post-Approval Study

Suggest Enhancement / Report Issue | export reports to excelExport to Excel
Study Status Delayed
Application Number /
Requirement Number
P130018 / PAS001
Date Original Protocol Accepted 11/02/2016
Date Current Protocol Accepted  
Study Name ProAct Post-Approval Study
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group No Control
Analysis Type Descriptive
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Objectives The ProACT PAS is a 5-year prospective, open-label, multi-center study designed to evaluate the long-term incidence of urethral stricture and device erosion after ProACT implantation. In addition, the study will evaluate whether treatment with ProACT affects clinical outcomes after subsequent SUI therapies.
Study Population Inclusion Criteria
1. Subject is a male of at least 50 years of age.
2. Subject demonstrates stress urinary incontinence.
3. Subject has undergone a radical prostatectomy, transurethral resection of the prostate, or other prostate surgery.
4. Subject is willing and able to undergo surgical implantation of ProACT devices.
5. Subject is willing and able to comply with study-required
follow-up activities, including annual telephonic follow –up interviews, for a period of 5 years from their date of initial implantation. This includes compliance even after possible explant of ProACT devices and/or possible implantation of subsequent therapies.
6. Subject is willing and able to sign the approved informed consent.
7. Subject has two positive 24-hour pad weight tests (greater than or equal to 8 gram pad weight increase demonstrated in two 24-hour pad weight tests).
8. Subject has a negative urine culture.
9. Subject has no known urogenital malignancy, other than previously treated prostate cancer.
10. Subject meets ONE of the following criteria:
a. Baseline PSA less than or equal to 2.5ng/mL;
b. Baseline PSA > 2.5ng/mL and less than or equal to 10 ng/mL AND free PSA greater than or equal to 25% of total PSA;
11. Physician determines subject to be a suitable surgical candidate.
Exclusion Criteria
1. Subject has an existing urethral stricture, a history of any urethral strictures, or has ever had a urethrotomy.
2. Subject has undergone prostate surgery or any anti-incontinence surgery within the last 12 months.
3. Subject has an artificial urinary sphincter or any components of a previously implanted artificial urinary sphincter in vivo.
4. Subject has undergone radiation therapy in the prostatic area within the last 12 months.
5. Subject has untreated or unsuccessfully treated detrusor instability or over-activity.
6. Subject has an atonic bladder.
7. Subject had, presently has, or is suspected of having bladder cancer.
8. Subject has untreated or unsuccessfully treated bladder stones.
9. Subject has detrusor sphincter dyssynergia.
10. Subject has known hemophilia or a bleeding disorder.
11. Subject has a known severe contrast solution allergy (e.g., anaphylaxis, cardiac, or respiratory arrest).
12. Subject has insulin-dependent diabetes that is uncontrolled or not controllable, as indicated by an A1c test result of = 6.5%.
Sample Size 145 subjects will be enrolled at 5 to 7 clinical sites in the U.S.
Key Study Endpoints 1. Cumulative incidence of ProACT-related clinically relevant urethral strictures over 5 years of follow up.
2. Cumulative incidence of ProACT device erosions over 5 years of follow-up.
3. Incontinence Quality of Life Questionnaire (I-QoL) over 5 year of follow-up.
4. Choice of subsequent SUI therapy(ies) post ProACT treatment.
Follow-up Visits and Length of Follow-up 5 years

ProAct Post-Approval Study Reporting Schedule

Reporting Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
6 month report 05/24/2016 05/23/2016 On Time
1 year report 11/23/2016 11/23/2016 On Time
18 month report 05/24/2017 05/22/2017 On Time
2 year report 11/23/2017 11/22/2017 On Time
30 month interim report 05/23/2018 05/23/2018 On Time
3 year report 11/23/2018 11/27/2018 Overdue/Received
42 month report 05/23/2019 05/23/2019 On Time
4 year report 11/23/2019 11/20/2019 On Time
5 year report 11/22/2020 11/23/2020 Overdue/Received
70 month report 09/16/2021 09/14/2021 On Time
74 month report 01/16/2022 01/13/2022 On Time
78 month report 05/16/2022 05/13/2022 On Time
82 month report 09/16/2022 09/15/2022 On Time
86 month report 01/16/2023 04/06/2023 Overdue/Received
90 month report 05/16/2023 05/11/2023 On Time

Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources